report provid updat
new sale driver focu
margin in-lin guidanc enough
stock trade sale
impact suppli chain issu long-term stori intact
path label expans may long wind reiter
rais pt improv earn profil
crsp indic move clinic bcma car-t
report strategi remain track
previou safeti notic classifi class recal
quick glanc
analyst certif import disclosur see
top-lin outlook in-lin forecast structur step
preclin pk/pd data huntington myoton
impact extra week coronaviru help current
fda green light phase aml trial pt
mcrpc preview ahead asco-gu present
kol highlight opportun pah market pt
rais curtain characterist
quarterli updat point pipelin catalyst easl
tumor biopsi analysi build confid
longer twofer move perform
updat focu ph timelin
top stori week report slight beat vs opco/street core segment result
larg line expect compani note cost-trend remain stabl cost-trend bottom
end initi rang bp trend expect rang follow quarter issu
ep guidanc compar opco/street prior estim
report provid updat
report non-gaap net loss vs estim phase program wet continu
progress enrol nors us expect complet may top-lin data nors
australia anticip august timelin impli potenti launch also spa agreement phase trial dme
brvo secur caution potenti near-term financ dilut believ otlk ev greatli
undervalu commerci opportun develop sole on-label bevacizumab multipl retin
disord multi-billion dollar wet market alon
new sale driver focu
sale y/i ahead januari pre-announc our/street origin
oper margin well ahead versu origin solid sg leverag better
gm sale guidanc reiter continu leverag expect despit new dtc
continu invest competit dynam continu bear watch near-term tailwind remain
includ overal strong cgm market growth pharmaci channel expans recent medicar launch solid intern
expans look ahead type penetr increasingli look promis dtc expect roll pump
partner launch build on-track full roll-out believ drive market expans share
margin in-lin guidanc enough stock trade sale
shockwav report revenu slightli consensu estim us revenu
y/i ou revenu y/i estim respect allow
ask question call henc idea contribut clinic vs commerci sale guid
introduc bracket consensu estim prior estim compani
believ dcb volum partial rebound data report key player seem reflect base
analysi shockwav valuat current sale estim impli margin beat in-lin guidanc
enough
impact suppli chain issu long-term stori intact
post rev slightli lower consensu estim respect
growth as-report basi impact continu product run shortfal jotec supplier
suppli issu tmr manufactur rev came lower end guidanc
note suppli issu probabl impact number total essenc compani would
post high-single-digit growth rate beat origin guidanc ye suppli issu frustrat long-term
valu proposit remain unchang proact xa remain biggest call option name
report decent financi result provid guidanc key upcom catalyst jakafi net sale
beat our/consensu estim guidanc midpoint previou
consensu estim pipelin discuss featur potenti fda-approv includ pemigatinib cca
pdufa tafasitamab dlbcl mor capmatinib nsclc limber program includ
jakafi combin pim poc data expect year plu jakafi qd-dose develop enabl
potenti fixed-dos combin data data bd remain
prioriti cash updat model actual detail insid
path label expans may long wind reiter perform
thursday agio report earn review recent progress effort expand tibsovo label continu
anticip snda file cholangiocarcinoma year-end given bristol-my recent withdraw idhifa r/r aml
see increas risk agio european regulatori strategi howev manag pursu new expans opportun
r/r md reopen md cohort opinion major catalyst focu primarili mitapivat
top-lin data activ activate-t studi expect eha anticip clinic updat mitapivat
thalassemia sickl cell anemia sca catalyst expect june given tibsovo slower expect
pace label expans believ share fairli price reiter perform
report result includ invelti revenu lower consensu estim
respect manag continu expect phase eysuvi trial data acut treatment episod dri
eye flare end assum posit nda resubmiss like remain buyer
current trade level believ eysuvi approv may address unmet need dri eye diseas market us
market potenti maintain pt ahead anticip eysuvi readout
rais pt improv earn profil
increas price target follow teva result better consensu
earn estim bullish improv bottom line driven factor within manag control
 margin improv remain cautiou top-lin growth driver await continu execut new generic/
biosimilar launch pipelin matur acknowledg near-term stock volatil relat opioid litig highli like
pt continu incorpor litigation-rel cash outflow year includ
increment litig risk premium discount rate remain comfort teva well posit manag
payment continu delev key concern mani investor
provid updat financi result busi highlight net loss vs estim
result year-end cash loss better estim net loss guidanc
includ share-bas comp lead year-end cash would provid sever year
runway encourag progress prasinezumab parkinson diseas data part
attr amyloidosi data updat late continu work preclin tau
antibodi program partner updat model actual guidanc detail insid
crsp indic move clinic bcma car-t
crsp report earn ep cash includ novemb offer rais
mark first year clinic data crispr engin scd tdt note initi data two patient
promis tdt patient total hb level reach incl hbf surpass bar hb scd
patient hbf reach month four beat expect total hb level patient free
voc expect updat crsp execut well trial indic ye r/rnhl
data bcma mm start enrol target solid tumor enter clinic
commerci revenu line off-set higher opex vs
increas spend earli matur data oral zytiga/xtandi-refractori mcrpc continu show
intrigu well-toler clinic activ without neutropenia/neurotox typic anti-tubulin addit tumor
type explor clinic candid zuclomiphen enter ph adt-associ hot flash long-act
gnrh antagonist hormone-sensit prostat cancer tadfin anticip approv continu move forward
accord plan believ market undervalu veru promis uro-oncolog pipelin asset well abil
shoulder develop activ effici commerci cash gener reduc concern equiti dilut
report strategi remain track
report adj ep vs opco/street estim adj result exclud
amort acq /integr cost off-set tax result slightli top expect core
segment roughli line estim follow quarter issu ep guidanc
compar opco/street prior result tweak ep estim
overal result outlook appear larg expect long-term outlook remain
track earli success healthhub traction modern effort synergi
previou safeti notic classifi class recal
fda post letter today announc classif previou urgent field safeti notif initi
class recal issu involv insulin pump advis patient back novemb
potenti safeti risk due miss broken retain ring occur pump impact hard surfac
drop etc ring lock reservoir pump fda letter agenc indic receiv
total relat complaint awar injuri one death sens isnt new action
ground requir classif versu compani commun patient letter novemb
chang manufactur reinforc retain ring last year thu recent/new product affect pump
need return unless ring damag replac patient still warranti expect
notic near-term impact issu overal increment neg diabet busi look stem share
quick glanc
report adj ep vs opco/street estim adj result exclud
amort acq /integr cost off-set tax result slightli top expect core
segment roughli line estim retail vs opco pharmaci vs opco/street
health benefit vs opco/street addit mbr slightli higher
opco follow quarter issu ep guidanc compar opco/street
overal result outlook appear larg expect
top-lin look in-lin forecast structur step push time-to-profit
provid financi guidanc disclos first believ could seri bolt-on
acquisit leverag newli acquir precis oncolog sale channel acquisit combin aggress
spend compani liquid biopsi franchis result guidanc come forecast view
increas intens structur compon merg exact sciences-genom infrastructur
offer potenti upsid surpris revenu forecast begin also push time profit net
take ep respect
help inform perspect amrn trial anda filer dr reddi hikma end spoke
three patent attorney close follow case discuss indic gener unlik succeed
invalid somewhat better albeit still low prospect non-infring win slightli pessimist
believ consensu project near certainti amrn broadli prevail caution signific downsid
potenti upon decis amrn driven elimin exit expect addit earli loss vascepa
exclus although share could ralli success litig would expect strength short-liv fail
materi investor focu increasingli valuat reiter under-perform
increment delay trilog result mid-feb announc monday disappoint market
nonetheless allow acst complet on-going clinic site audit discuss find conclus
fda potenti regulatori guidanc could construct treatment trilog data prior
unblind recal five site deem suspect also particip yet contribut much smaller
fraction subject vs given expect appear wash ev yet current cash
suffici reduc opex believ restor investor confid capr success develop
would upsid share
preclin pk/pd data huntington myoton dystrophi come
recent met neubas nbse ceo/cfo receiv updat regard expect upcom
preclin data huntington diseas hd myoton dystrophi type pk biodistribut data includ
penetr deep brain structur cell permeabl come first follow pd activ data name select
knockdown mhtt mutant huntingtin gene along also look safeti off-target effect
preclin model etc import box need check enter clinic nbse acceler
preclin stori greater confid upcom valu inflect point especi due consist
manag tone execut updat model nbse first stay bullish
impact extra week coronaviru help current demand santa clara closur benefit earlier
rev beat estim extra sell week benefit gm pressur
stronger-than-expect medic rev vs estim opex pressur extra sell week
 rev estim see increas diagnost detector demand amid
china coronaviru wuxi facil expect reopen next week though shift product contin
santa clara facil closur benefit expect hit full quarter earlier full year benefit expect
final cfo clarenc verhoef retir fy continu like bread-and-butt imag stori
fda green light phase aml trial pt
tuesday marker announc fda lift clinic hold plan phase aml trial place due
issu relat reagent suppli third-parti base fda feedback protocol amend includ
safeti lead-in cohort includ patient receiv multitaa manufactur legaci reagent
patient receiv product newly-sourc reagent enrol legaci set proceed immedi
enrol revis set must await final test supplier expect resolut provid clear
path forward marker anticip modest delay develop timelin due lead-in reiter
outperform pt
mcrpc preview ahead asco-gu present
asco-gu includ updat mcrpc cohort basket trial thursday ccrpc
expand twice patient registration-en estim enrol patient
could complet median follow-up month orr includ two recal mcrpc
patient limit option upon progress abirateron enzalutamid mcrpc often receiv docetaxel
enrol patient post two a/e one-third fail docetaxel a/e orr consist across
patient subtyp safety/toler favor new signal view earli atezolizumab cabozantinib
data promis compar dataset set typic reach orr
kol highlight opportun pah market pt sotatercept
host teleconfer yesterday two pulmonari arteri hypertens pah expert better understand sever
aspect disord includ current state diagnosi evolut treatment combin novel candid
develop physician serv investig phase pulsar trial sotatercept express
much enthusiasm follow recent report top-lin result driven much sotatercept novel mechan action
efficaci safeti although report pulsar data remain limit base avail result specialist
optimist drug potenti assum signific role within pah treatment paradigm follow discuss
revis model includ global commerci sotatercept expect launch
sotatercept achiev ww peak sale may prove conserv rais pt
maintain outperform rate
astella issu updat result ev keytruda previous untreat muc patient
elig treatment cisplatin-bas chemotherapi previou updat esmo note
orr dcr new datacut median follow-up month present fri
asco-gu orr remain stabl pr median
reach month os rate earli profil chemo -free
regimen look compel vs keytruda monotherapi orr tecentriq platinum-bas chemo
show orr esmo
rais curtain characterist
present detail keyston symposium outlin characterist develop decis
engin tcr differenti car-t may offer advantag clinic preserv normal
physiolog use natur occur receptor broader address target lower gvhd risk collabor
ircc ospedal san raffael previous show esgct knockout endogen t-cell receptor tcr
insert wilm tumor tcr achiev homogen product tgtcr chain pair
trac insert trbc ko use promot select lead tcr show cytokin releas
degranul peptid stimul activ patient-deriv aml blast liver front present
prekallikrein ko strategi hereditari angioedema
drop coverag vlrx previous rate perform follow compani announc file
voluntari petit chapter us bankruptci code seek sale compani via asset sale
zealand pharma zeal announc bid bankruptci sale process acquir vlrx all-cash
consider term deal zealand agre acquir substanti vlrx asset
assum certain liabil relat on-going busi vlrx file voluntari petit chapter propos
sale conduct court-supervis sale process subject court-approv bid procedur
quarterli updat point pipelin catalyst easl
report financi result includ hcv royalti estim consensu
estim guidanc hcv sale drive estim vs consensu
royalti featur upcom pipelin catalyst includ rsvp data expect addit
rsv studi initi nash trial initi pbc intrepid data
expect follow-on fxr-agonist nash studi initi preclin pk/pd data
present core-inhibitor hbv data support dose detail
addit studi viremic-hbv patient initi lower pt detail
tumor biopsi analysi build confid
imv tsx also trade present translat dpx-survivac data asco-sitc show survivin-specif
cell induct patient cohort dpx-survivac induc immun cell infiltr tumor tissu
anti-tumor respons correl dpx-survivac induc t-cell infiltr activ t-cell remain function
data provid addit support mechan action ahead top-lin data
open-label studi evalu efficaci dpx-survivac low-dos cyclophosphamid late-lin ovarian cancer
imv end strong note data spirel evalu dpx-survivac pembrolizumab low-dos
cyclophosphamid r/r dlbcl next step dlbcl meet fda formul registr
program could commun
longer twofer move perform
follow bhvn announc today regard troriluzol failur meet phase primari endpoint gener
anxieti disord gad move perform rate lower price target continu
posit skew bhvn lead asset rimegep acut treatment migrain probabl regulatori
success howev current trade level believ stock present fair reflect risks/reward associ
asset upsid current trade may relat posit phase rimegep prevent trial downsid
sub-optimal acut label and/or potenti safeti consider complet denial nda highli unlik view note
recent complet fundrais well posit launch rimegep
updat focu ph timelin
xair report revenu licens revenu estim consensu estim
ep vs estim consensu estim compani reiter plan pphn
us approv commerci launch without new partner replac circassia termin decemb
despit delay pma mid/late-april estim compani hold investor day march
hope time addit updat pphn would avail
report adcetri sale royalti below/abov est
consensu est guidanc adcetri consensu guidanc vs
consensu adcetri revenu light vs consensu prompt discuss
call view modest growth matur asset adcetri eighth year natur focus emerg
products/asset follow last year strong track record pivot studi padcev/tucatinib look toward one pivot
program tisotumab vedotin tv metastatic-cerv cancer meanwhil padcev launch way joint
salesforc astella tucatinib file expect fda decis file accept soon
feb expert call ind investig new drug file
feb piedmont atlanta hospit visit atlanta relev ew
event chicago amrn acst mist ew
may oppenheim med-tech day san francisco ca
may biotech summit featur chemistri life process institut
juli montauk summit emerg life scienc
sept fall summit focus specialti pharma diseas gene therapi new york ny
oct houston oncolog summit md anderson cancer center
healthcar provid manag
